Insulet Co. (NASDAQ:PODD) – Analysts at Leerink Swann cut their Q1 2018 EPS estimates for Insulet in a research report issued on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical instruments supplier will earn ($0.15) per share for the quarter, down from their previous forecast of $0.02. Leerink Swann also issued estimates for Insulet’s Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at $0.05 EPS, Q4 2018 earnings at $0.00 EPS, FY2018 earnings at ($0.21) EPS, Q1 2019 earnings at $0.07 EPS, Q2 2019 earnings at $0.11 EPS, Q3 2019 earnings at $0.19 EPS, FY2019 earnings at $0.45 EPS and FY2020 earnings at $0.93 EPS.
Several other research analysts have also recently issued reports on the company. Jefferies Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insulet in a research report on Friday. Canaccord Genuity upped their price objective on Insulet from $78.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday. Zacks Investment Research cut Insulet from a “hold” rating to a “sell” rating in a research report on Friday. Cowen reaffirmed an “outperform” rating and set a $90.00 price objective (up from $80.00) on shares of Insulet in a research report on Thursday. Finally, Oppenheimer set a $82.00 price objective on Insulet and gave the stock a “hold” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $72.19.
Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.04). The business had revenue of $130.50 million for the quarter, compared to analyst estimates of $125.16 million. Insulet had a negative return on equity of 39.74% and a negative net margin of 5.79%. The company’s revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) earnings per share.
Several institutional investors have recently bought and sold shares of PODD. Frontier Capital Management Co. LLC lifted its holdings in shares of Insulet by 42.4% in the 4th quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock valued at $144,633,000 after purchasing an additional 624,465 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Insulet in the 3rd quarter valued at about $33,373,000. Millennium Management LLC lifted its holdings in shares of Insulet by 154.1% in the 4th quarter. Millennium Management LLC now owns 941,567 shares of the medical instruments supplier’s stock valued at $64,968,000 after purchasing an additional 571,082 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Insulet by 328.2% in the 4th quarter. Renaissance Technologies LLC now owns 661,200 shares of the medical instruments supplier’s stock valued at $45,623,000 after purchasing an additional 506,800 shares during the last quarter. Finally, Fred Alger Management Inc. lifted its holdings in shares of Insulet by 32.5% in the 4th quarter. Fred Alger Management Inc. now owns 1,808,616 shares of the medical instruments supplier’s stock valued at $124,795,000 after purchasing an additional 443,970 shares during the last quarter.
TRADEMARK VIOLATION NOTICE: “Research Analysts Set Expectations for Insulet Co.’s Q1 2018 Earnings (PODD)” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3222282/research-analysts-set-expectations-for-insulet-co-s-q1-2018-earnings-podd.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.